Bayer Healthcare's decision came after the successful mid-stage testing results of the drug. Finally its ambition to enter into the cardiovascular medicine is getting fulfilled through this drug.
The company said, "We are ready to conduct the expansion of the clinical development program for the oral, non-steroidal mineralocorticoid receptor antagonist finerenone, or BAY 94-8862 with Phase III studies."
The drug finerenone will be tested for its efficacy and safety on patients with diabetic kidney disease and chronic heart failure in the final trial. It is planning to enroll around 3,600 patients for the trial by the end of 2015.
The mid-stage testing of the drug showed positive outcomes which involved four dosage studies in patients with kidney disease due to diabetes or a chronic heart failure. The drug is expected to hit the market by 2020 or 2021.
"We are excited about finerenone being the first mineralocorticoid receptor antagonist that is being developed in parallel in chronic heart failure and diabetic kidney disease. The studies will investigate whether finerenone can reduce cardiovascular morbidity and mortality as well as the progression of renal disease in these patients with a well-tolerated safety profile," said Joerg Moeller, head of Global Development at Bayer.